Loading…
Alkem Laboratories (ALKEM)₹5,399+1.78%Pharmaceuticals
At the end of the Jun 2026 quarter, Alkem Laboratories' shareholders were: promoters 49.76%, FIIs 10.45%, DIIs 22.62%, public 17.17%. Promoter holding is down 1.50 percentage points from 51.26% a quarter earlier. FII holding is up 1.31 percentage points from 9.14% a year earlier. It had 62,812 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 56.80% | 56.80% | 56.80% | 56.44% | 55.72% | 55.72% | 55.19% | 53.10% | 51.26% | 51.26% | 51.26% | 49.76% |
| FIIs | 6.06% | 8.52% | 9.14% | 8.72% | 9.05% | 10.17% | 9.43% | 9.14% | 9.50% | 10.00% | 10.18% | 10.45% |
| DIIs | 17.61% | 15.89% | 15.61% | 18.54% | 19.19% | 17.99% | 19.40% | 21.78% | 21.91% | 21.52% | 21.37% | 22.62% |
| Public | 19.53% | 18.79% | 18.45% | 16.30% | 16.04% | 16.12% | 15.98% | 15.98% | 17.33% | 17.22% | 17.19% | 17.17% |
| Number of shareholders | 69,431 | 65,174 | 65,820 | 69,616 | 74,732 | 84,025 | 84,313 | 79,727 | 67,185 | 64,526 | 62,825 | 62,812 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Sarandhar Singh * (please refer notes) | Promoter | 18.32% | −0.46 |
| Basudeo Narain Singh | Promoter | 7.28% | 0.00 |
| Mritunjay Kumar Singh | Promoter | 6.39% | 0.00 |
| Madhurima Singh& (please refer notes) | Promoter | 6.23% | 0.00 |
| Hdfc Mutual Fund - Hdfc Mid-Cap Fund | DII | 4.80% | +0.71 |
| Icici Prudential Multi-Asset Fund | DII | 3.59% | +0.47 |
| Madhurima Singh@ (please refer notes) | Promoter | 2.61% | 0.00 |
| Kishor Kumar Singh | Public | 2.48% | 0.00 |
| Alok Kumar | Public | 2.30% | 0.00 |
| Ashok Kumar | Public | 2.26% | 0.00 |
| Seema Singh | Promoter | 2.14% | 0.00 |
| Deepak Kumar Singh | Public | 2.03% | 0.00 |
| Archana Singh | Promoter | 2.01% | 0.00 |
| Sbi Large & Midcap Fund | DII | 2.00% | −0.43 |
| Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap Fund | DII | 1.88% | −0.06 |
| Dsp Midcap Fund | DII | 1.79% | +0.33 |
| Nps Trust- A/C Hdfc Pension Fund Management Limited Scheme E - Tier I | DII | 1.47% | +0.13 |
| Life Insurance Corporation Of India - P & Gs Fund | DII | 1.44% | −0.13 |
| Rajesh Kumar | Public | 1.42% | 0.00 |
| Hdfc Life Insurance Company Limited | DII | 1.30% | −0.02 |
| Rajeev Ranjan | Public | 1.25% | 0.00 |
| Divya Singh& (please refer notes) | Promoter | 1.02% | 0.00 |
| Meghna Singh | Promoter | 1.02% | 0.00 |
| Shrey Shree Anant Singh | Promoter | 1.01% | 0.00 |
| Aniruddha Singh& (please refer notes) | Promoter | 1.00% | 0.00 |
Promoters held 49.76% of Alkem Laboratories at the end of the Jun 2026 quarter, down 3.34 percentage points from 53.10% a year earlier.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 10.45% (up 0.27 percentage points from 10.18% a quarter earlier) and domestic institutions (DIIs) held 22.62% (up 1.25 percentage points from 21.37% a quarter earlier).
Alkem Laboratories had 62,812 shareholders at the end of the Jun 2026 quarter, against 79,727 a year earlier.
Hdfc Mutual Fund - Hdfc Mid-Cap Fund (DII) held 4.80% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.